Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 326

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 326
---
 grant, generally equal to the vesting period, on a straight-line basis. We determine
the estimated fair value of each stock option on the date of grant using the Black-Scholes valuation model which uses assumptions regarding
a number of complex and subjective variables. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent
with the expected term of the option in effect at the time of the grant. Expected volatility is based on an analysis of the historical
volatility of a peer group of companies. The expected term represents the period that we expect our stock options to be outstanding.
The expected term assumption is estimated using the simplified method set forth in the U.S. Securities and Exchange Commission’s
Staff Accounting Bulletin Topic 14, which is the mid-point between the option vesting date and the expiration date. We have never declared
or paid dividends on our common stock and have no plans to do so in the foreseeable future. Changes in these assumptions may lead to
variability with respect to the amount of stock compensation expense we recognize related to stock options.

Recently
Issued Accounting Pronouncements

Certain
recently issued accounting pronouncements are discussed in Note 2, Significant Accounting Policies, to the consolidated financial statements
included in Item 8. “Financial Statements and Supplementary Data” of this Annual Report.

Item
7A. Quantitative and Qualitative Disclosures About Market Risk.

We
are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise
required under this Item 7A.

70

Item
8. Financial Statements and Supplementary Data.

INDAPTUS
THERAPEUTICS, INC.

CONSOLIDATED
FINANCIAL STATEMENTS

TABLE
OF CONTENTS

    Page
  
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB name: HASKELL & WHITE LLP and PCAOB ID: 200)
     
    F-2
  
    CONSOLIDATED
    FINANCIAL STATEMENTS:

    Consolidated Balance Sheets as of December 31, 2024 and 2023
     
    F-3
  
    Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023
     
    F-4
  
    Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2024 and 2023
     
    F-5
  
    Consolid